Gair, Gair, Conason, Rubinowitz, Bloom, Hershenhorn, Steigman & Mackauf is a New York Plaintiff's personal injury law firm specializing in automobile accidents, construction accidents, medical malpractice, products liability, police misconduct and all types of New York personal injury litigation.

Articles Tagged with product liability

Published on:

Fentanyl.jpgThe FDA has received several reports of wrongful death, including two children since April 2012 when it warned the public about the danger of accidental exposure to fentanyl patches. For this reason, manufacturers are now required to use a more visible ink to print the name and the strength of the drug on the patches.

Exposure to fentanyl patches can cause serious injury and death to children, pets and others.

Accidental exposure may happen if a used patch is not disposed of properly or if a patch accidentally falls from a patients skin.

Published on:

2005-Toyota-Sienna.jpgToyota announced a new car recall in the US yesterday because a defective lever system in some Sienna minivans can cause the vehicles to shift out of park mode “without the driver depressing the brake pedal” and resulting in a vehicle roll-away. 24 accidents related to the defective car have been reported to Toyota so far. The recall affects approximately 615,000 Sienna minivans from Model Years 2004-2005 and 2007-2009. This is the second time in a month that Toyota has issued a recall of its vehicles in the US market. Earlier this month, the car manufacturer issued a recall for more than 780,000 vehicles to address a defective suspension in its RAV4 and Lexus HS 250h models.

Nissan also announced yesterday that it was recalling nearly a million defective cars worldwide because a defective accelerator sensor could cause the car to stall. No accidents have been reported so far according to the manufacturer. The recall affects Infiniti M, Serena, X-Trail, Lafesta and Fuga models produced in Japan between 2004 and 2013.

Published on:

A new study published in CANCER, a peer-reviewed journal of the American Cancer Society, shows that Amioradone, marketed since 1985 and used for arrhythmia or irregular heartbeats may increase cancer especially for patient using large doses.